November 22, 2022 Paradigm Biopharmaceuticals CEO, Marco Polizzi, to step down SYDNEY, Australia: Paradigm Biopharmaceuticals, a late-stage drug development company focused on delivering new therapies to address unmet medical needs, announced that its CEO, Mr…
September 9, 2022 NeuroScientific Biopharmaceuticals CEO & MD Matt Liddelow resigned SYDNEY: NeuroScientific Biopharmaceuticals announced the resignation of its CEO and Managing Director, Mr Matt Liddelow effective immediately. NSB’s Chairman Mr Paul Rennie said, “I…
July 13, 2022 Paradigm Biopharmaceuticals partners with NFL Alumni Health on Osteoarthritis Program SYDNEY: Paradigm Biopharmaceuticals Ltd (ASX:PAR), a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, has entered…
September 18, 2023 Hemogenyx Pharmaceuticals gets $830,000 investment and signs deal with CRO for CAR-T trial Hemogenyx Pharmaceuticals plc, a biopharmaceutical company developing new treatments for blood diseases, has secured a $830,000 investment from Prevail Partners, an investment fund. The…
August 17, 2023 Arecor partners with top 10 pharma company to develop novel antibody formulation LONDON, UK: Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to enable healthier lives, announced today that it has signed an agreement with…
January 9, 2023 AstraZeneca partners LBT Innovations for APAS pharma development ADELAIDE, AUSTRALIA: Australian medical technology company LBT Innovations Limited (ASX: LBT) has been engaged by AstraZeneca for the full product development for its APAS…
November 30, 2022 AstraZeneca announces sale of West Chester site LONDON, United Kingdom: AstraZeneca announced the sale of its West Chester site in Ohio, US, to National Resilience, Inc. (Resilience), a technology-focused manufacturing company…
September 5, 2022 Lytix Biopharma appoints Stephen Worsley as Chief Business Officer OSLO: Lytix Biopharma, a Norwegian immune-oncology company, announced the appointment of Stephen Worsley as Chief Business Officer (CBO). Stephen Worsley is a pharmaceutical executive…
September 5, 2022 Forxiga approved in China for CKD LONDON: AstraZeneca‘s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR)…
August 30, 2022 Neurocrine Biosciences agrees to acquire Diurnal Group LONDON: Neurocrine Biosciences, a neuroscience-focused biopharmaceutical company, has agreed to acquire Diurnal Group. The acquisition values the entire issued and to be issued ordinary…